as of 03-02-2026 3:52pm EST
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 1.5B | IPO Year: | 2005 |
| Target Price: | $28.75 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.35 | EPS Growth: | -27.47 |
| 52 Week Low/High: | $3.91 - $19.11 | Next Earning Date: | 03-23-2026 |
| Revenue: | $7,539,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | -25.03% | Revenue Growth (next year): | -71.24% |
| P/E Ratio: | -7.40 | Index: | N/A |
| Free Cash Flow: | -130278000.0 | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Chief Medical Officer
Avg Cost/Share
$15.00
Shares
2,437
Total Value
$36,555.00
Owned After
0
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$17.10
Shares
42,544
Total Value
$727,319.46
Owned After
0
SEC Form 4
Director
Avg Cost/Share
$15.11
Shares
9,300
Total Value
$140,477.43
Owned After
206,547
SEC Form 4
Avg Cost/Share
$15.70
Shares
60,000
Total Value
$942,240.00
Owned After
8,265,000
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Ribeiro Ramiro | EYPT | Chief Medical Officer | Feb 17, 2026 | Sell | $15.00 | 2,437 | $36,555.00 | 0 | |
| Ribeiro Ramiro | EYPT | Chief Medical Officer | Jan 5, 2026 | Sell | $17.10 | 42,544 | $727,319.46 | 0 | |
| Lurker Nancy | EYPT | Director | Dec 4, 2025 | Sell | $15.11 | 9,300 | $140,477.43 | 206,547 | |
| Cormorant Asset Management, LP | EYPT | Other | Dec 4, 2025 | Sell | $15.70 | 60,000 | $942,240.00 | 8,265,000 |
See how EYPT stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "EYPT EyePoint Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.